Suppr超能文献

通过正电子发射断层扫描测量单次口服组胺H1拮抗剂后人类大脑中组胺H1受体占有率。

Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography.

作者信息

Yanai K, Ryu J H, Watanabe T, Iwata R, Ido T, Sawai Y, Ito K, Itoh M

机构信息

Department of Pharmacology I, Tohoku University School of Medicine, Sendai, Japan.

出版信息

Br J Pharmacol. 1995 Sep;116(1):1649-55. doi: 10.1111/j.1476-5381.1995.tb16386.x.

Abstract
  1. Histamine H1 receptor occupancy in the human brain was measured in 20 healthy young men by positron emission tomography (PET) using [11C]-doxepin. 2. (+)-Chlorpheniramine, a selective and classical antihistamine, occupied 76.8 +/- 4.2% of the averaged values of available histamine H1 receptors in the frontal cortex after its administration in a single oral dose of 2 mg. Intravenous administration of 5 mg (+)-chlorpheniramine almost completely abolished the binding of [11C]-doxepin to H1 receptors (H1 receptor occupancy: 98.2 +/- 1.2%). 3. Terfenadine, a nonsedative antihistamine, occupied 17.2 +/- 14.2% of the available H1 receptors in the human frontal cortex after its administration in a single oral dose of 60 mg. 4. There was no correlation between H1 receptor occupancy by terfenadine and the plasma concentration of the active acid metabolite of terfenadine in each subject. 5. PET data on human brain were essentially compatible with those on H1 receptor occupancy in guinea-pig brain determined by in vivo binding techniques, although for the same H1 receptor occupancy the dose was less in human subjects than in guinea-pigs. 6. The PET studies demonstrated the usefulness of measuring H1 receptor occupancy with classical and second-generation antihistamines in human brain to estimate their unwanted side effects such as sedation and drowsiness quantitatively.
摘要
  1. 采用正电子发射断层扫描(PET)技术,使用[11C] - 多塞平,对20名健康年轻男性的人脑中组胺H1受体占有率进行了测量。

  2. 选择性经典抗组胺药(+) - 氯苯那敏单次口服2 mg后,占据额叶皮质中可用组胺H1受体平均值的76.8±4.2%。静脉注射5 mg(+) - 氯苯那敏几乎完全消除了[11C] - 多塞平与H1受体的结合(H1受体占有率:98.2±1.2%)。

  3. 非镇静性抗组胺药特非那定单次口服60 mg后,占据人额叶皮质中可用H1受体的17.2±14.2%。

  4. 特非那定的H1受体占有率与各受试者体内特非那定活性酸代谢物的血浆浓度之间无相关性。

  5. 人脑海马体的PET数据与通过体内结合技术测定的豚鼠脑海马体H1受体占有率的数据基本相符,尽管对于相同的H1受体占有率,人体受试者的剂量低于豚鼠。

  6. PET研究证明,在人脑中用经典和第二代抗组胺药测量H1受体占有率,对于定量评估其诸如镇静和嗜睡等不良副作用是有用的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验